Valeant Pharmaceuticals sees 40 pct higher revenue, profit in 2014

Tue Jan 7, 2014 8:20am EST

Jan 7 (Reuters) - Valeant Pharmaceuticals International Inc , Canada's largest listed drugmaker, on Tuesday forecast 2014 adjusted earnings of $8.25 to $8.75 per share and revenue of $8.2 billion to $8.6 billion, both up about 40 percent from the previous year.

Analysts on average were expecting 2014 adjusted earnings per share of $8.71 and revenue of $8.279 billion, according to Thomson Reuters I/B/E/S.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.